Date of submission of the HTAC Recommendation: 20 July 2026Date of notification to HTAC on the SOH decision: 26 August 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology through Department continue reading : HTA Council Final Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology
HTA Council Final Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
Date of submission of the HTAC Recommendation: 20 July 2026Date of notification to HTAC on the SOH decision: 26 August 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists continue reading : HTA Council Final Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
HTA Council Preliminary Recommendation on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC)
As of 14 July 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC). The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments continue reading : HTA Council Preliminary Recommendation on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC)
HTA Council Preliminary Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
As of 16 June 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic continue reading : HTA Council Preliminary Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
HTA Council Preliminary Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology
As of 16 June 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of levothyroxine sodium 12.5 micrograms (mcg) and 25mcg tablets for the management of hypothyroidism of any etiology. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from continue reading : HTA Council Preliminary Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology